logo-loader
RNS
viewCreo Medical Group PLC

First in-human cases in India

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.8pt;margin-bottom:.0001pt;text-align:justify;font-size:8.5pt;font-family:"Arial","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .bq{size:595.3pt 841.9pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.bq{}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: center}span.cv{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.cw{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}span.cq{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: center}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; text-align: center} p.da{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}span.ck{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.cl{background:white}span.bl{}p.db{margin-right:0cm;margin-left:0cm;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.dc{color:black}span.bp{}span.ch{color:black;background:white}span.ci{color:black}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} span.de{color:black}span.df{color:black}p.dg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal}p.dh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}p.di{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.bj{}p.dj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}p.dk{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}p.dl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}table.dm{margin-left:-5.4pt;border-collapse:collapse} td.bz{width:215.75pt;padding:0cm 5.4pt 0cm 5.4pt}td.bx{width:272.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: right}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:normal}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height: normal}p.dq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: right; text-indent: -101.2pt}p.dr{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}p.ds{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:normal}p.dt{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify} /**/
RNS Number : 9711T
Creo Medical Group PLC
20 November 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

First in-human cases in India

Asia's First POEM procedure undertaken using Speedboat

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the first mentored, in-human use of its Speedboat device has taken place in India. This announcement follows on from the framework distribution agreement the Company signed with Meditek Systems in September 2019 to provide clinical in-country training, mentoring and market seeding in India for Creo's CROMA Advanced Energy Platform and suite of products.

To date, Medical staff from six key healthcare institutions across India have completed training as part of Creo's Clinical Education Programme and the start of in-country mentoring was marked with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat. These are the first POEM procedures in India carried out using the Speedboat device and show the significant advances made towards the future of endoscopic surgery.

The procedures were performed by Dr Amit Maydeo and Dr Gaurav Patil at the BIDS (Baldota Institute of Digestive Sciences) hospital in Mumbai. Dr Maydeo is currently the Chairman of the BIDS hospital and President of the Association of Interventional GI Endoscopy of India. Both cases were highly successful with Dr Maydeo citing "the microwave coagulation aspect of this device is excellent and not having to interchange devices mid-procedure makes this a great advancement in technology''. With further mentored clinical cases planned in the coming days in Delhi, Pune and Hyderabad, the expansion of Speedboat and the CROMA Advanced Energy Platform continues to gather pace.

 

As well as India and the US, patients have now been successfully treated using the Speedboat device powered by Creo's CROMA Advanced Energy platform in the UK, South Africa and Mainland Europe.

 

About Speedboat

Creo's Speedboat device is the first in a range of GI devices to be cleared for use with the CROMA Advanced Energy Platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. 

 

Craig Gulliford, Chief Executive Officer, commented: "We are delighted to hear that Creo's Speedboat device has been rolled out in the BIDS hospital and that the first live procedures have been a success, and are due to be followed by other procedures this week. India is one of the fastest growing healthcare markets in the world and is rapidly evolving in pioneering clinical practice. We look forward to further positive news on the subsequent surgeries."

 

 

Creo Medical Group plc

investors.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Cameron MacRitchie (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238

 

 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAMMMMMRLFGLZM

Quick facts: Creo Medical Group PLC

Price: 175.25

Market: LSE
Market Cap: £263.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE